Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Bintrafusp alfa + FPV-Brachyury + MVA-BN-Brachyury + Nogapendekin alfa inbakicept |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bintrafusp alfa | MSB0011359C|M7824 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 TGFBR2 Antibody 3 | Bintrafusp alfa is a human PD-L1 (CD274) antibody fused with transforming growth factor-beta (TGF-beta, TGFBR2) receptor II extracellular domain, which blocks two immuno-inhibitory pathways simultaneously, therefore enhances anti-tumor immunity (PMID: 29298798, PMID: 32461347). | |
FPV-Brachyury | FPV-Brachyury-TRICOM Vaccine | FPV-Brachyury is a putative vaccine that infects cells and induces expression of the brachyury protein protein to elicit an immune response (Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019) 2640-2640, PMID: 31876334). | ||
MVA-BN-Brachyury | MVA-BN-Brachyury is a poxvirus-based immunotherapy that targets Brachyury-expressing tumor cells (Journal of Clinical Oncology 33, no. 15_suppl (May 20 2015) 3079-3079, PMID: 31876334). | |||
Nogapendekin alfa inbakicept | Anktiva | N-803|N803|N 803|nogapendekin alfa|ALT803|ALT 803|ALT-803 | Anktiva (nogapendekin alfa inbakicept) is a fusion protein comprising a mutant version of IL-15 with increased activity and IL-15Ra fused to the Fc region of IgG1, which activates CD8+ T-cells and promotes effector activity, potentially resulting in increased antitumor immune response (PMID: 24404427, PMID: 31338557). Anktiva (nogapendekin alfa inbakicept) in combination with BCG is FDA approved for use in patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03493945 | Phase Ib/II | Bintrafusp alfa + Epacadostat + FPV-Brachyury + MVA-BN-Brachyury + Nogapendekin alfa inbakicept Bintrafusp alfa + FPV-Brachyury + MVA-BN-Brachyury Bintrafusp alfa + FPV-Brachyury + MVA-BN-Brachyury + Nogapendekin alfa inbakicept Bintrafusp alfa + Nogapendekin alfa inbakicept | Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1). | Active, not recruiting | USA | 0 |